Johannes Zanzinger, PhD


Johannes studied Animal Sciences and Biology, and earned a PhD in Animal Sciences (Dr. sc.agr.) at the University of Hohenheim in 1992, followed by postdoctoral positions at the Medical Faculties of the Universities of Freiburg and Heidelberg, where he completed a postdoctoral thesis (Habilitation) and was appointed Associate Professor (Privatdozent) for Physiology in 1998.  Johannes then started his industrial career in 1999 as a Group Leader for in vivo Pharmacology at Pfizer Global Research & Development (Sandwich, UK).  He joined Boehringer Ingelheim in Research Coordination in 2002, and became Global Head of Business Development and Licensing for Cardiometabolic Diseases in 2009.  In this function, he identified, championed and negotiated multiple partnerships with pharma, biotech and academia, and served on the Therapeutic Area Leadership Committee for Cardiometabolic Diseases.

In addition to his role at Boehringer Ingelheim, Johannes still continues to act as an adjunct (Apl) Professor of Physiology at the University of Ulm.  Johannes also serves as board member of HepaRegenix in Tübingen, DiogenX in Marseille, Eyevensys in Paris, and AgoMab in Ghent.